Skip to content

Study · Animal study (in vivo) · rat · 2003

9 results

GH responses to GHRH and GHRP-6 in Streptozotocin (STZ)-diabetic rats.

Diz Chaves Y, Spuch Calvar C, Pérez Tilve D, Mallo Ferrer F

Life sciences1 Nov 2003Cited by 4 (Europe PMC)

PMID14572879 (opens in a new tab)DOI10.1016/j.lfs.2003.06.026 (opens in a new tab)PepBankPUB-14572879
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In STZ-diabetic rats, GH responses to GHRP‑6 increased with dose.

    In plain wordsIn rats with STZ-induced diabetes, GH responses to GHRP‑6 increased with dose.

    Peptide
    GHRP-6
    Outcome
    IncreaseDose-dependent GH response in STZ rats
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH responses to GHRP-6 occurred in a dose-dependent manner in STZ-rats, but not in controls.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In control rats, GH responses to GHRP‑6 did not show dose dependence.

    In plain wordsIn control rats, GH responses to GHRP‑6 did not increase with dose.

    Peptide
    GHRP-6
    Outcome
    No significant changeDose dependence in controls
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH responses to GHRP-6 occurred in a dose-dependent manner in STZ-rats, but not in controls.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In STZ-diabetic and control rats, GH responses to GHRP‑6 were lower than responses to GHRH.

    In plain wordsIn diabetic and control rats, GHRP‑6 produced lower GH responses than GHRH.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH response versus GHRH
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH responses to GHRP-6 in both groups were clearly lower than those elicited by GHRH.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

Studies that did not test the peptide alone6

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In STZ-diabetic rats, GH AUC after GHRP‑6 was higher than in control rats.

    In plain wordsIn STZ-diabetic rats, GH AUC after the GHRP‑6 challenge was higher than in control rats.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH AUC at high dose
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Comparator
    Control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    GH responses to 30 microg/Kg of GHRP-6 were significantly greater in STZ-rats than in controls (AUC: 3549.9 +/- 1001.4 vs. 2046.4 +/- 711.7; p<0.05).
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In diabetic and control rats, GHRH plus GHRP‑6 produced the strongest GH stimulus.

    In plain wordsIn diabetic and control rats, the combined peptides stimulated GH more strongly than either peptide alone.

    Peptide
    GHRP-6
    Outcome
    IncreaseCombined stimulus potency
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Comparator
    Individual secretagogues
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The combined administration of GHRH plus GHRP-6 was the most potent stimuli for GH in both groups.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In diabetic and control rats, low-dose GHRH plus GHRP‑6 produced a synergistic GH peak.

    In plain wordsIn diabetic and control rats, low doses of the combined peptides produced a synergistic GH peak.

    Peptide
    GHRP-6
    Outcome
    IncreaseLow-dose combination synergy
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The administration of doses in the lower range (1 + 3 microg/Kg, GHRH + GHRP-6 respectively) induced a great peak of GH in STZ-rats and in control rats, revealing a synergistic effect of GHRH and GHRP-6 in both groups.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In STZ-diabetic rats, GH at time 5 after high-dose GHRH plus GHRP‑6 was lower than in controls.

    In plain wordsIn diabetic rats, GH at time 5 after the high-dose combined test was lower than in controls.

    Peptide
    GHRP-6
    Outcome
    DecreaseHigh-dose combination GH at time 5
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Comparator
    Control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    When the higher doses were administered (10 + 30 microg/kg), GH levels in time 5, and AUC were significantly higher in control rats.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  5. 08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In STZ-diabetic rats, GH AUC after high-dose GHRH plus GHRP‑6 was lower than in controls.

    In plain wordsIn diabetic rats, the overall GH response to the high-dose combined test was lower than in controls.

    Peptide
    GHRP-6
    Outcome
    DecreaseHigh-dose combination GH AUC
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Comparator
    Control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    When the higher doses were administered (10 + 30 microg/kg), GH levels in time 5, and AUC were significantly higher in control rats.
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  6. 09AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Activity measurement

    In STZ-diabetic rats, weight tendency correlated negatively with GH AUC after GHRP‑6.

    In plain wordsIn diabetic rats, lower weight tendency was linked to higher GH responses after GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    DecreaseWeight tendency and GH AUC
    Study

    ratsn: not reported in source

    STZ-diabetic and control rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In addition, a negative correlation between WT (weight tendency) values and GH responses, represented as AUC, could be established in STZ-rats (r2=-0.566, p=0.004 for GHRH; r2=-0.412, p=0.028 for GHRP-6).
    2 context sentences
    Summary · context
    GH responses to GHRH, the physiologic hypothalamic stimulus, and GHRP-6, a synthetic hexapeptide that binds the Ghrelin receptor, were studied in rats treated with streptozotocin (STZ), an experimental model of diabetes.
    Summary · context
    GH responses were challenged with two different doses of GHRH (1 and 10 microg/kg) or GHRP-6 (3 and 30 microg/kg) and with a combination of both at low (1 + 3 microg/kg) or high (10 + 30 microg/kg) doses, respectively.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.